Renaissance Technologies LLC Has $242,000 Holdings in OptiNose, Inc. (NASDAQ:OPTN)

Renaissance Technologies LLC decreased its stake in shares of OptiNose, Inc. (NASDAQ:OPTN) by 17.3% during the second quarter, HoldingsChannel.com reports. The fund owned 233,100 shares of the company’s stock after selling 48,800 shares during the period. Renaissance Technologies LLC’s holdings in OptiNose were worth $242,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in OPTN. HighMark Wealth Management LLC bought a new stake in shares of OptiNose during the 1st quarter worth $36,000. Oracle Investment Management Inc. bought a new position in shares of OptiNose during the 1st quarter worth about $474,000. Easterly Investment Partners LLC grew its holdings in shares of OptiNose by 34.0% during the 1st quarter. Easterly Investment Partners LLC now owns 2,038,039 shares of the company’s stock worth $2,976,000 after purchasing an additional 516,730 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in OptiNose by 2.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,920,309 shares of the company’s stock worth $3,037,000 after buying an additional 81,233 shares in the last quarter. Finally, Kingdon Capital Management L.L.C. raised its position in OptiNose by 5.4% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,899,237 shares of the company’s stock worth $5,030,000 after purchasing an additional 200,000 shares in the last quarter. 85.60% of the stock is owned by institutional investors.

OptiNose Trading Up 3.1 %

Shares of OPTN opened at $0.67 on Friday. The stock has a 50 day simple moving average of $0.87 and a 200-day simple moving average of $1.03. OptiNose, Inc. has a 1 year low of $0.65 and a 1 year high of $2.10. The stock has a market cap of $75.78 million, a PE ratio of -2.48 and a beta of -0.05.

OptiNose (NASDAQ:OPTN) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. The firm had revenue of $20.49 million for the quarter, compared to analyst estimates of $20.81 million. On average, sell-side analysts forecast that OptiNose, Inc. will post -0.22 EPS for the current fiscal year.

Insider Activity

In related news, insider Michael F. Marino III sold 49,408 shares of the company’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $1.14, for a total transaction of $56,325.12. Following the transaction, the insider now owns 550,464 shares in the company, valued at $627,528.96. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Ramy A. Mahmoud sold 111,426 shares of the company’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $1.14, for a total value of $127,025.64. Following the completion of the sale, the chief executive officer now owns 1,206,978 shares in the company, valued at approximately $1,375,954.92. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Michael F. Marino III sold 49,408 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $1.14, for a total value of $56,325.12. Following the transaction, the insider now owns 550,464 shares in the company, valued at approximately $627,528.96. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 167,679 shares of company stock worth $191,154. 2.70% of the stock is owned by corporate insiders.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.